Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease

Çolak, Yaşar; Şenateş, Ebubekir; Öztürk, Oğuzhan; Doganay, Levent; Çoşkunpınar, Ender; Oltulu, Yasemin Müşteri; Eren, Ali Erhan; Şahin, Önder; Özkanlı, Şeyma; Enç, Feruze Yılmaz; Ulasoglu, Celal; Tuncer, İlyas

doi:10.1089/met.2011.0111

Cited by 18 publications

(21 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fads expression has been found to be negatively associated with hepatic fat content, and FADS can suppress the accumulation of hepatic lipids . In addition, YZH liquid decreased the expression levels of Pla2 family members, which are upstream checkpoints regulating fatty acid uptake that are upregulated in patients with NASH . The knockout of Pla2 has been proven to achieve a 56.5% decrease in fatty acid influx in hepatocytes .…”

Section: Discussionmentioning

confidence: 99%

“…25 In addition, YZH liquid decreased the expression levels of Pla2 family members, which are upstream checkpoints regulating fatty acid uptake that are upregulated in patients with NASH. 26,27 The knockout of Pla2 has been proven to achieve a 56.5% decrease in fatty acid influx in hepatocytes. 26 The administration of YZH liquid also increases the expression of alcohol dehydrogenase, the impairment of which has been noticed in the liver tissue of NASH patients.…”

Section: Network-based Regulatory Model Of Yzh Liquid On Nashmentioning

confidence: 99%

See 1 more Smart Citation

Effects and therapeutic mechanism of Yinzhihuang on steatohepatitis in rats induced by a high‐fat, high‐cholesterol diet

Zeng

Liu

Xin

et al. 2020

J of Digest Diseases

View full text Add to dashboard Cite

Objectives We aimed to investigate the therapeutic mechanism of Yinzhihuang (YZH) liquid, a traditional Chinese medicine mainly composed of extracts of four components, on nonalcoholic steatohepatitis (NASH) induced by a high‐fat, high‐cholesterol diet (HFHCD) in rats. Methods Altogether 30 Sprague‐Dawley rats were randomized into three groups: control, the model group (HFHCD + saline) and the treatment group (HFHCD + YZH). Liver histological features and serum biochemical parameters were assessed by the end of the 16th week. RNA sequencing and protein mass spectrometry detection were performed. The genes and proteins expressed differentially were subjected to KEGG pathway enrichment analysis and included in a network‐based regulatory model. Results The weight, liver and fat indices and serum alanine transaminase, aspartate transaminase and total cholesterol levels of the HFHCD + YZH group were all significantly lower than those of the HFHCD + saline group. Moreover, their hepatic steatosis, ballooning and lobular inflammation were relieved, and 64 hepatic genes and 73 hepatic proteins were found to be reversed in their expression patterns after YZH treatment (P < 0.05). The network‐based regulatory model showed that these deregulated genes and proteins were mainly involved in oxidative phosphorylation, Toll‐like receptor, nucleotide‐binding oligomerization domain‐like receptor, peroxisome proliferator‐activated receptor signaling, nuclear factor‐kappa B tumor necrosis factor signaling pathways and fatty acid metabolism. Conclusion YZH could alleviate NASH in HFHCD‐fed rats by inhibiting lipogenesis, accelerating lipid β‐oxidation, alleviating oxidative stress and relieving necroinflammation in the liver.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Network-based Regulatory Model Of Yzh Liquid On Nashmentioning

confidence: 99%

Effects and therapeutic mechanism of Yinzhihuang on steatohepatitis in rats induced by a high‐fat, high‐cholesterol diet

Zeng

Liu

Xin

et al. 2020

J of Digest Diseases

View full text Add to dashboard Cite

show abstract

“…The sPLA 2 is one of the main factors associated with progression of inflammatory disease (e.g. cardiovascular disease) and the serum level of lipoprotein-associated phospholipase A 2 was found to be elevated in NAFLD [7]. The enzyme plays a role by the activation of low-density lipoprotein (LDL) oxygenation and recruitment of macrophages to the atherosclerotic plaque [6].…”

Section: Discussionmentioning

confidence: 99%

“…The role of sPLA 2 during progression of inflammation in NAFLD is practically unknown. However, lipoprotein-associated phospholipase A 2 was recently characterized as a novel inflammatory biomarker that is correlated with several components constituting the metabolic syndrome [7].…”

Section: Introductionmentioning

confidence: 99%

Secretory phospholipase A 2 activity is linked to hypercholesterolemia and gender in non-alcoholic fatty liver disease individuals

Raszeja‐Wyszomirska¹,

Safranow²,

Szynkowska³

et al. 2013

View full text Add to dashboard Cite

“…Therefore, additional studies that determine the effects of Lp‐PLA2 inhibition alone or in combination with periodontal treatments on the risk of CVD in CP patients are valuable for the control of CVD. Additionally, both positive and negative associations between plasma Lp‐PLA2 levels and nonalcoholic fatty liver disease (NAFLD) were demonstrated in epidemiological studies, and Lp‐PLA2 seemingly protected subjects against the initiation and progression of NAFLD . However, considering the observation that lysoPC administration could induce hepatitis in vivo, contrary to the protective role of Lp‐PLA2, further investigations using a longitudinal design is necessary to identify the cause.…”

Section: Biological Functions and Disease Implicationsmentioning

confidence: 99%

Lipoprotein‐associated phospholipase A2: The story continues

Huang

Wang

Shen

2019

Medicinal Research Reviews

131

140

View full text Add to dashboard Cite

Inflammation is thought to play an important role in the pathogenesis of vascular diseases. Lipoprotein‐associated phospholipase A2 (Lp‐PLA2) mediates vascular inflammation through the regulation of lipid metabolism in blood, thus, it has been extensively investigated to identify its role in vascular inflammation‐related diseases, mainly atherosclerosis. Although darapladib, the most advanced Lp‐PLA2 inhibitor, failed to meet the primary endpoints of two large phase III trials in atherosclerosis patients cotreated with standard medical care, the research on Lp‐PLA2 has not been terminated. Novel pathogenic, epidemiologic, genetic, and crystallographic studies regarding Lp‐PLA2 have been reported recently, while novel inhibitors were identified through a fragment‐based lead discovery strategy. More strikingly, recent clinical and preclinical studies revealed that Lp‐PLA2 inhibition showed promising therapeutic effects in diabetic macular edema and Alzheimer's disease. In this review, we not only summarized the knowledge of Lp‐PLA2 established in the past decades but also emphasized new findings in recent years. We hope this review could be valuable for helping researchers acquire a much deeper insight into the nature of Lp‐PLA2, identify more potent and selective Lp‐PLA2 inhibitors, and discover the potential indications of Lp‐PLA2 inhibitors.

show abstract

Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease

Abstract: Although subject to future confirmation, our data suggest that Lp-PLA2 levels are elevated in NAFLD.

Cited by 18 publications

References 31 publications

Effects and therapeutic mechanism of Yinzhihuang on steatohepatitis in rats induced by a high‐fat, high‐cholesterol diet

Effects and therapeutic mechanism of Yinzhihuang on steatohepatitis in rats induced by a high‐fat, high‐cholesterol diet

Secretory phospholipase A 2 activity is linked to hypercholesterolemia and gender in non-alcoholic fatty liver disease individuals

Lipoprotein‐associated phospholipase A2: The story continues

Contact Info

Product

Resources

About